Novocure (NVCR) Stock Analysis & Winston Score

Novocure is a medical device company that makes a cancer treatment called Tumor Treating Fields, or TTFields. Instead of drugs or radiation, TTFields uses low-intensity electrical fields delivered through patches worn on the body to slow or stop cancer cells from dividing. The main product is called Optune, and it is used to treat brain cancer (glioblastoma) as well as other solid tumors like lung and ovarian cancer. Novocure makes money by renting or selling its Optune devices to patients, mostly through insurance reimbursement, with revenue tied to the number of active patients using the system each month. The company operates primarily in the United States, Europe, and Japan. Its main competitive advantage is that TTFields is a unique, patented technology with no direct equivalent on the market. The biggest risk is reimbursement coverage — if insurers refuse to pay for the treatment in new cancer indications, growth in the patient base will be limited.